• CANNABIS ORCHARDS

New Partnership Improves Availability of CBC Industrial Hemp in Canada

Updated: Aug 23


Cannabis Orchards Partners with USA-based Genetics Company Front Range Biosciences to Offer High CBC Industrial Hemp Varieties in Canada


As featured in the Greenhouse Grower: https://www.greenhousegrower.com/crops/new-partnership-improves-availability-of-cbc-industrial-hemp/


Ottawa, CANADA (June 30, 2022) – Cannabis Orchards Inc., a biotechnology company focusing on the research, development and commercialization of minor cannabinoids and innovative industrial hemp varieties, announced it has signed an exclusive partnership agreement with Front Range Biosciences (FRB), an American cannabis and hemp genetics platform company based in Boulder, Colorado that specializes in creating and introducing new innovative products, by combining their own innovative agricultural technologies with their world renowned hemp and cannabis Research & Development program.


Cannabis Orchards Inc. will exclusively distribute feminized hemp seed from select Front Range Biosciences varieties and genetics in Canada, which align with the collective goal of making available hemp varieties rich in minor cannabinoids, upon approval by Health Canada. These varieties include:


· Valerie-16:

o Cannabichromene (CBC) rich strain, 24-28:1 CBD:THC, 13-16% CBD, 3-4% CBC when grown under optimal conditions

o Rich in terpenes Myrcene and Caryophyllene which lend themselves to give this variety its aroma of musk, clove, herbal, citrus, wood, and spice.

· Valerie-29:

o CBD and CBC Dominant Sativa, 26-30:1 CBD:THC, 15-18% CBD, 3-5% CBC when grown under optimal conditions

o Dominantly citrus in aroma. Rich in terpenes Myrcene and Caryophyllene which lend themselves to give this variety its aroma of musk, clove, herbal, citrus, wood, and spice.


Statement from Cannabis Orchards CEO, Dr. Jamie Ghossein


“The partnership agreement with FRB will enable us to scale the production of cannabichromene, making this novel cannabinoid available to cannabis companies and consumers across Canada. More importantly, this will finally allow us to lend this novel cannabinoid for study to researchers and clinicians across Canada, allowing us to develop new therapeutic options for patients and the medicinal market.”


Potential CBC Benefits

CBC has been largely unavailable in the Canadian hemp market up until recently. Even now, CBC is often undetectable and found in trace amounts. Many plants considered to be high in CBC only exhibit a concentration of 0.4-0.8% CBC. By introducing Valerie-16 and Valerie-29 which can yield CBC up to 3-4% availability drastically increases the yield for cannabis extractors. With interest in CBC increasing and more scientific evidence on the benefits of CBC being published now is the perfect time to get into the market with CBC-predominant products.


CBC, like all other minor cannabinoids, comes from the mother of all cannabinoids, Cannabigerol (CBG). However, unlike CBG, which is only expressed in higher concentrations at the reduction of other therapeutic cannabinoids, CBC is able to be expressed in tandem with higher concentrations of therapeutic cannabinoids like CBD. It is hypothesized that there is an entourage effect when CBC is combined with other cannabinoids.


What makes CBC unique is its molecular structure which interacts with the human immune system. CBC is able to interact with transient receptor potential (TRP) cation channels that inhibit endocannabinoid inactivation, and thus stimulate CB2 receptors. CBC does not have any significant activity at CB1 receptors, meaning it is a non-psychotropic cannabinoid, and will not alter perception or behaviour as THC does. CBC indirectly affects the endocannabinoid system as it stimulates the production of endocannabinoids, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG). The endocannabinoid system and transient receptor potential channel are both involved in inflammation and pain.


The growing body of research into the benefits of CBC shows a variety of therapeutic potentials. In vitro and in vivo studies recently published describe that CBC has anti-cancer activity, pain-relieving properties, ani-inflammatory properties and more. At Cannabis Orchards Inc., we see the value of minor cannabinoids and we hope to make CBC widely available to Canadian consumers, patients and researchers for potential therapeutic applications.


About Cannabis Orchards

Cannabis Orchards Inc. is an inventive, research-driven, and proudly Canadian company focused on furthering the development and commercialization of novel cannabinoids and therapeutics. The company leads research into the development of new hemp varieties, and their clinical applications. The company has an involved focus on producing the highest quality hemp flowers for their medicinal contents, namely for CBD and minor cannabinoids. The company was the first to produce certified feminized hemp seed in Canada. Cannabis Orchards products are highly sought after by Licensed Processors, research institutes and pharmaceutical companies. For more information on Cannabis Orchards Inc., visit https://www.cannabisorchards.ca


About Front Range Biosciences

Front Range Biosciences is a highly established cannabis and hemp genetics company, prioritizing the development of innovative new products for use across a multitude of industries. Front Range Biosciences has a world-renowned R&D program, complimented by their leading-edge agricultural technologies and practices. Front Range Biosciences prioritizes farmers and takes them into account every step of the way – from R&D to in field-testing. Front Range Biosciences dedication to the creation of new, efficient products, and the attention to addressing farmer needs is apparent through everything they do – from providing varieties of seeds, young plants, proprietary breeding, and tissue culture technologies. For more information on Front Range Biosciences, visit www.frontrangebio.com.